Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moexipril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 15/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moexipril SCHEMBL6508276 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL29376544 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL683321 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL22175779 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL34030 | 1.00 | ACE (1.00) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL5159178 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL40877 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL14660386 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL30903896 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 | |
| Moexipril SCHEMBL5386742 | 0.99 | ACE (0.98) | ACEPDE3AABCB11LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0096157-A2 | Substituted acyl derivatives of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid | WARNER-LAMBERT COMPANY (US) | 1983-12-21 | — | — | EP | claimed |
| US-4344949-A | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1982-08-17 | — | — | US | claimed |
| EP-0049605-A1 | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids, salts thereof, pharmaceutical compositions containing the derivatives or salts, and the production of the same | WARNER-LAMBERT COMPANY (US) | 1982-04-14 | — | — | EP | claimed |
| US-8394813-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7427600-B2 | Active agent delivery systems and methods for protecting and administering active agents | SHIRE LLC (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-0049605-B1 | SUBSTITUTED ACYL DERIVATIVES OF 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACIDS, SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR SALTS, AND THE PRODUCTION OF THE SAME | WARNER-LAMBERT COMPANY (US) | 1987-03-18 | — | — | EP | disclosed |
| US-4532342-A | N-substituted amino acids as intermediates in the preparation of acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0096157-A2 | Substituted acyl derivatives of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid | WARNER-LAMBERT COMPANY (US) | 1983-12-21 | — | — | EP | disclosed |
| US-4344949-A | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
| EP-0049605-A1 | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids, salts thereof, pharmaceutical compositions containing the derivatives or salts, and the production of the same | WARNER-LAMBERT COMPANY (US) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885PDE3A 203/4885ABCB11 4659/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885PDE3A 478/4885ABCB11 4712/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885PDE3A 413/4885ABCB11 4566/4885 |
| US-20070232529-A1 | mesalamine covalently attached to carrier peptide at C-terminus, interspersed and/or side chain; releasing into bloodstream; reducing dosage | VIP, BST2, FCGR3B | ACE 948/4885PDE3A 821/4885ABCB11 307/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885PDE3A 488/4885ABCB11 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.